Drug Trial Radar · NCT03358472
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
89
Actual
Start
Dec 1, 2017
Primary completion
Jul 19, 2018
Study completion Oct 30, 2025
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Nov 30, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Conditions
- Head and Neck Cancer
Interventions
PembrolizumabDrug
Pembrolizumab administered intravenously every 3 weeks.
EpacadostatDrug
Epacadostat administered orally twice daily.
CetuximabDrug
Cetuximab administered intravenously on Cycle 1 Day 1 followed by administration every week.
CisplatinDrug
Cisplatin administered intravenously every 3 weeks for \</= 6 cycles.
CarboplatinDrug
Carboplatin administered intravenously every 3 weeks for \</= 6 cycles.
5-FluorouracilDrug
5-Fluorouracil administered intravenously every 3 weeks for \</= 6 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) of Pembrolizumab + Epacadostat, Pembrolizumab Monotherapy and the EXTREME RegimenTime frame: Minimum Week 9
Locations
73 sites in 14 countries. Site status is shown where the registry gives one.
Pacific Cancer Medical Center
Anaheim, California
UC Davis Comprehensive Cancer Center
Sacramento, California
St. Joseph Heritage Healthcare
Santa Rosa, California
University of Colorado Cancer Center
Aurora, Colorado
Yale Cancer Center
New Haven, Connecticut
Northwest Georgia Oncology Centers PC
Douglasville, Georgia
U of Kansas Cancer Center
Westwood, Kansas
Baptist Health
Louisville, Kentucky
St. Vincent Healthcare Cancer Ctr
Billings, Montana
New Mexico Cancer Care Alliance
Albuquerque, New Mexico
Oklahoma Cancer Specialists and Research
Tulsa, Oklahoma
Providence Portland Med Center
Portland, Oregon
Huntsman Cancer Institute Univ of Utah
Salt Lake City, Utah
Viginia Mason Med Ctr
Seattle, Washington
Chris OBrien Lifehouse
Camperdown, New South Wales, Australia
Macquarie University Hospital
North Ryde, New South Wales, Australia
Royal Brisbane & Women s Hospital
Herston, Queensland, Australia
Landeskrankenhaus Salzburg
Salzburg, Austria
Allgemeines Krankenhaus der Stadt Wien
Vienna, Austria
Juravinski Cancer Center Hamilton Health Sciences
Hamilton, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
CHU de Quebec-Universite Laval-Hotel Dieu de Quebec
Québec, Quebec, Canada
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz
Miskolc, Hungary
Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet
Szolnok, Hungary
Istituto Europeo di Oncologia
Milan, Italy
IRRCS Instituto Clinico Humanitas
Rozzano, Italy
Hyogo Cancer Center
Akashi, Japan
Kyushu University Hospital
Fukuoka, Japan
Hiroshima University Hospital
Hiroshima, Japan
Hokkaido University Hospital
Hokkaido, Japan
Kobe City Medical Center General Hospital
Kobe, Japan
Saitama Cancer Center
Saitama, Japan
Kindai University Hospital
Sayama, Japan
Shizuoka Cancer Center Hospital and Research Institute
Shizuoka, Japan
The Cancer Institute Hospital of JFCR
Tokyo, Japan
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, Japan
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
Miyagi Cancer Center
Natori-shi, Miyagi, Japan
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.